All In Biotech

Drug Trial Radar · NCT03932864

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

A Randomized, Placebo-Controlled, Ascending Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of MGTA-145 in Healthy Subjects Administered as a Single Agent, as Well as in Combination With Plerixafor

Last checked: Nov 20, 2026Latest source record: Jan 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

107

Actual

Start

Apr 22, 2019

Primary completion

Feb 25, 2020

Study completion Feb 25, 2020

Sponsor

Lead sponsor
EnsomaIndustry
Sponsor type
Industry
First posted
May 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MGTA-145 in healthy volunteers as a single agent and in combination with plerixafor.

Conditions

  • Healthy Volunteers

Interventions

  • MGTA-145Biological

    MGTA-145 will be given in various doses intravenously

  • plerixaforBiological

    240 µg/kg subcutaneously

  • PlaceboBiological

    Placebo will be given in various doses intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as measured by incidence of treatment-emergent adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs).Time frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medpace CPU

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.